Heuron Signs Strategic MOU with Siemens Healthineers Korea

2024-01-15


Heuron, a medical AI startup focused on neurological disorders based in South Korea, has signed a strategic business Memorandum of Understanding (MOU) with Siemens Healthineers for the supply of brain neuroimaging AI software.

 

Under this MOU, Heuron and Siemens Healthineers Korea will establish a close cooperation framework based on their respective expertise and infrastructure to advance and commercialize brain neuroimaging analysis AI software. Siemens Healthineers Korea will support the expansion of brain neuroimaging analysis solutions in South Korea by leveraging its MRI equipments and collaborating with comprehensive hospitals and diagnostic centers.

 

Founded in 2017, Heuron specializes in medical AI for neurological disorders and holds proprietary technology for implementing diagnostic logic of clinical experts into AI models for diseases such as Parkinson’s, dementia, and stroke. The company commercialized the first Parkinson’s disease diagnostic assistance AI software in South Korea and achieved FDA approval and CE certification for its self-developed dementia analysis software.

 

Siemens Healthineers, headquartered in Germany, is a global leader in healthcare innovation. The company supplies products and solutions in areas such as imaging diagnostics, in vitro diagnostics, cancer treatment, and minimally invasive therapies, utilizing advanced digital technologies and AI.

 

Dr. Donghoon Shin, CEO of Heuron, stated, “In a global landscape where many medical AI companies are striving to secure a competitive edge in the South Korean market and expand internationally, we are pleased that this MOU will allow Heuron to advance further. We will strive to achieve significant business expansion through continuous mutual cooperation with Siemens Healthineers, a leader in global imaging diagnostics.”